|Name||PRICE||MARKET CAPITALIZATION||PRICE TO EARNINGS RATIO||DIVIDEND YIELD||SYMBOL||EXCHANGE||PRICE PERCENT DIFFERENCE||YEAR TO DATE PRICE PERCENT DIFFERENCE||5 YEAR CHART||1 YEAR CHART|
Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis. Next-generation Ultomiris was recently approved in paroxysmal nocturnal hemoglobinuria. Strensiq and Kanuma target other ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need and complement-mediated disorders.
ALXN $130.21 -4.00 (-2.98%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 29.72 Billion
EPS -0.20 P/E Ratio 372.03
Previous Earnings Wed, Oct 24, 2018
Latest Earnings Mon, Feb 4, 2019
Dividend Pay Date --
Dividend History --
Investing Quotes #Legendary
Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.
Some links on this website are advertisements and/or affiliate links and Symbol Surfing receives compensation.